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Abstract
The activity of mupirocin (Bactroban) against coagulase-posi-
tive and coagulase-negative staphylococci isolated in a burns
unit was tested to ascertain its effectiveness, and to detect any
resistant isolates after continuous use of mupirocin for 2.5
years. A total of 395 staphylococci, consisting of 330 Staphylo-
coccus aureus and 65 coagulase-negative staphylococci, were
tested for resistance to mupirocin and other antimicrobial
agents. The results showed that 94.5% of the isolates were fully
susceptible to mupirocin (MIC ^4 mg/l), and 5.3% expressed
low-level resistance (MIC 8–128 mg/l). One Staphylococcus
haemolyticus isolate expressed high-level resistance (MIC
11,024 mg/l). It transferred high-level mupirocin resistance to
other staphylococci in conjugation experiments, which indi-
cated a capacity to transmit mupirocin resistance between spe-
cies. The results demonstrated that mupirocin was still highly
effective against staphylococci in the burns unit. However, the
demonstration that the resistant S. haemolyticus isolate could
transfer high-level mupirocin resistance to other staphylococci
was of concern. There is a compelling need to test staphylococ-
ci from clinical materials for mupirocin resistance. Early
detection of resistance can prevent the establishment and
spread of the mupirocin-resistant strains in the unit.
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Introduction
Mupirocin (Bactroban) is a naturally oc-
curring antibiotic produced by Pseudomonas
fluorescens. It inhibits bacterial protein syn-
thesis by binding reversibly and specifically to
bacterial isoleucyl transfer-RNA synthetase
[1, 2]. Because of its excellent antistaphylo-
coccal activity, mupirocin has been used to
eradicate nasal carriage of methicillin-resis-
tant Staphylococcus aureus (MRSA) in pa-
tients and healthcare workers [3–8], in the
control of MRSA outbreaks [3, 9], in the treat-
ment of infections of wounds, burns, ulcers
and eczema [3, 7, 8, 10], as a prophylaxis
before skin surgery [11], and for the reduction
of staphylococcal load in atopic dermatitis
[12, 13]. Mupirocin is very safe and does not
appear to have any significant side effects.
According to Moy et al. [14], no side effects
were reported in patients after 4 years of treat-
ment with mupirocin. It does not stain the
skin or displace the host’s normal flora [15].
In addition, it is structurally unrelated to any
of the antibiotics in current use and there is no
cross-resistance with them [15]. It was also
found to be superior to topical antiseptics
such as chlorhexidine, silver sulfadiazine, po-
vidone iodine and azelaic acid because with
these antiseptics, a significant number of
MRSA usually persist after treatment [16].
These properties provide a compelling argu-
ment in favor of using mupirocin for treat-
ing burn wound infections, especially those
caused by MRSA. Sadly, despite these quali-
ties, plasmid-encoded high-level resistance to
mupirocin has occurred in staphylococci iso-
lated in some countries [17–20]. In a few
instances the emergence of mupirocin resis-
tance has been attributed to its prolonged use
[6, 14].
MRSA is a persistent isolate in burns pa-
tients at the Ibn Sina Hospital, Kuwait. Sub-
sequently mupirocin was introduced here in
1992 to treat burn wound infections and to
eradicate nasal colonization in patients. The
burns unit at the Ibn Sina Hospital, Kuwait, is
a 70-bed special facility for treating burn pa-
tients for the whole of Kuwait. It has an inten-
sive care unit with 12 beds. The bed occupan-
cy in the burns unit is 70–100%. Both the nas-
al gel and skin ointments are administered to
patients according to the guidelines provided
by the manufacturer [15]. Although this treat-
ment protocol has been successful in control-
ling MRSA in treated patients, MRSA contin-
ued to persist in the unit. It was therefore nec-
essary to establish if staphylococci isolated in
the unit has become resistant to mupirocin,
which could, at least in part, explain the per-
sistence of MRSA in the unit. An early detec-
tion of resistant strains would warrant prompt
institution of appropriate infection control
measures to prevent their spread.
Materials and Methods
Bacterial Strains
A total of 395 staphylococci consisting of 230
MRSA, 100 methicillin-sensitive S. aureus (MSSA)
and 65 coagulase-negative staphylococci (CNS) iso-
lated from clinical materials and submitted to the
microbiology laboratory from patients between April
1994 and May 1995 were studied. The isolates were
from patients in the burns unit and were studied
whether or not the patients from whom they were iso-
lated had mupirocin therapy. Strains were initially
identified as S. aureus or coagulase-negative staphylo-
cocci by the tube coagulase test using rabbit plasma
(Difco Laboratories, Detroit, Mich., USA). The coagu-
lase-negative staphylococci were speciated according
to biochemical reactions using the API-20, Staph iden-
tification scheme (bioMérieux SA, Marcy-l’Étoile,
France). They consisted of S. epidermidis (n = 42),
S. haemolyticus (n = 9), S. saprophyticus (n = 6), S. si-
mulans (n = 4), S. hominis (n = 2), S. scuiri (n = 1) and
S. capitis (n = 1).
Antibiotic Susceptibility Testing
Antibiotic susceptibility testing was performed by
disk diffusion method on Mueller-Hinton agar accord-
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Table 1. Sources of the
staphylococcal isolates (%) Specimens MRSA MSSA CNS Total (%)
Blood 23 (10) 18 (18) 36 (55.3) 77 (19.5)
Swabs1 174 (75.6) 58 (58) 14 (21.5) 246 (62.2)
Fluids 5 (2.1) 6 (6) 4 (6.1) 15 (3.8)
ETS 4 (1.7) – – 4 (1.01)
Sputum 2 (0.8) 1 (1) 1 (1.5) 4 (1.01)
Urine – – 1 (1.5) 1 (0.2)
Catheter tips 4 (1.7) 4 (4) 5 (7.6) 13 (3.3)
Axillae 5 (2.1) 3 (0) – 8 (2.02)
Nasal swab 8 (3.4) 7 (7) 4 (6.1) 19 (4.8)
Groin 3 (1.3) 3 (3) – 6 (1.5)
HVS 2 (0.8) – – 2 (0.5)
Total 230 100 65 395
1 The swabs consisted of wound swabs, high vaginal swabs and ear
swabs.
ing to the NCCLS guidelines [21, 22]. For susceptibili-
ty to mupirocin, disks containing 5 and 200 Ìg mupiro-
cin (UniPath, Basingstoke, England) were used. For
susceptibility to other antibacterial agents, commercial
disks (UniPath) with the following concentrations of
antibacterial agents were used: methicillin (5 Ìg), peni-
cillin (10 Ìg), gentamicin (10 Ìg), kanamycin (30 Ìg),
neomycin (30 Ìg), streptomycin (30 Ìg), erythromycin
(15 Ìg), clindamycin (2 Ìg), chloramphenicol (30 Ìg),
tetracycline (10 Ìg), minocycline (30 Ìg), trimetho-
prim (2.5 Ìg), fusidic acid (10 Ìg), rifampicin (5 Ìg),
ciprofloxacin (5 Ìg), teicoplanin (30 Ìg), and vancomy-
cin (30 Ìg). For sensitivity to heavy metals and nucleic
acid-binding compounds 6-mm disks were impreg-
nated with antimicrobial agents: cadmium acetate
(50 Ìg), propamidine isethionate (50 Ìg), and ethidium
bromide (60 Ìg). Zone sizes for each antibiotic were
measured and compared to those produced by S. au-
reus ATCC 25923 and S. epidermidis ATCC 12228.
Minimum inhibitory concentration (MIC) to mupiro-
cin was determined by the agar dilution method using
a replicator instrument (Sigma Chemical Co.) with an
inoculum of 105 cfu/ml in Mueller-Hinton agar con-
taining doubling dilutions of the antibiotic with final
concentrations of 2–1,024 Ìg/ml. The plates were incu-
bated at 35 °C for 18 h and the MIC was recorded as
the lowest concentration of antibiotic which complete-
ly inhibited bacterial growth.
Genetic Manipulations
Attempts were made to transfer mupirocin resis-
tance from S. haemolyticus isolate CN216 to laborato-
ry recipients and clinical isolates of S. aureus and coa-
gulase-negative staphylococci in conjugation experi-
ments as described previously [23]. Donor and trans-
conjugants were screened for plasmid carried by the
cetyltrimethylammonium bromide method as de-
scribed previously [23].
Results
The 395 staphylococci studied were iso-
lated from different clinical materials which
are summarized in table 1. The majority, 246
(62.2%), of the isolates were from wound or
related swabs. However, the majority of the
CNS isolates were from blood cultures, an
indication of the growing importance of these
organisms in bloodstream infections. Al-
though mupirocin has not been used specifi-
cally to eradicate colonization by CNS, the
CNS isolates were tested for resistance to mu-
pirocin because CNS has been found to ex-
press high-level resistance to mupirocin which
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Table 2. Susceptibility of staphylococci to mupirocin
Isolates n Sensitive, %
MIC ^ 4 mg/l
Resistant, %
MIC 616 mg/l MIC 1512 mg/l
MRSA 230 219 (95.2) 11 (4.8) 0.0
MSSA 100 98 (98.0) 2 (2.0) 0.0
CNS 65 56 (86.2) 8 (12.3) 1 (1.5)a
Total 395 373 (94.5) 21 (5.3) 1 (0.2)
a This isolate had an MIC 11,024 mg/l.
Table 3. Resistance of the isolates to other antimi-
crobials
Antimicrobial agents % resistance
MRSA MSSA CNS
Methicillin 100.0 0.0 46.5
Penicillin G 100.0 86.0 80.0
Gentamicin 99.0 4.0 61.5
Tetracycline 94.8 46.0 44.6
Streptomycin 88.3 0.0 24.6
Trimethoprim 86.1 7.0 56.9
Erythromycin 66.5 7.0 63.1
Clindamycin 23.5 1.0 35.4
Ciprofloxacin 53.0 1.0 26.1
Chloramphenicol 25.2 2.0 32.1
Fusidic acid 21.7 0.0 24.6
Rifampin 0.9 0.0 12.3
Cadmium 96.5 47.0 47.7
Propamidine isethionate 11.6 7.4 17.2
Ethidium bromide 11.6 7.4 22.5
are borne on conjugative plasmids [18, 25].
All of the 395 isolates were tested for suscepti-
bility to mupirocin and other antimicrobial
agents. Their susceptibilities to mupirocin are
as summarized in table 2. The results showed
that 94% of the isolates were fully susceptible
(MIC ^ 4 mg/l).
Twenty-one (5.3%) of the 395 isolates ex-
pressed low levels of resistance (MIC 8–128
mg/l). One CNS isolate, identified as S. hae-
molyticus (CN216), expressed high-level re-
sistance (MIC 11,024 mg/l). They were all
susceptible to teicoplanin and vancomycin
but were resistant to the other antimicrobial
agents as shown in table 3. Resistance to gen-
tamicin, streptomycin, tetracycline, trimetho-
prim, erythromycin, clindamycin, ciprofloxa-
cin and fusidic acid was more common in
MRSA than in MSSA isolates. Also the
MRSA were more resistant to the non antibi-
otic agents, cadmium, propamidine isethion-
ate and ethidium bromide. Forty-six percent
of the CNS isolates were resistant to methicil-
lin. These were also more resistant to other
antimicrobial agents than the MRSA and
MSSA isolates.
In clinical laboratories, susceptibility to
mupirocin by the disk diffusion method is
usually performed with two disks, one con-
taining 5 Ìg and the other containing 200 Ìg
of mupirocin. The 5-Ìg disk is used to detect
low-level resistance while the 200-Ìg disk is
used to detect high-level resistance. There-
fore, for each isolate, two mupirocin disks are
needed. Both disks could be used together on
the same test plate or the 5-Ìg disk is used first
to detect the presence of low-level resistance
followed by the use of the 200-Ìg disk to con-
firm high-level resistance. This is technically
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Table 4. Comparison of MIC values with zone
diameters using different mupirocin disk concentra-
tions
MIC, mg/l Zone 5 Ìg Diameters 200 Ìg
^4 25–30 36–42
8 18–20 32–34
16 14–16 28–30
32 8–10 25–26
64 6 22–24
128 6 14–16
1512 6 6
laborious, time-consuming and costly. In this
study, we compared zone sizes obtained by
the two mupirocin disk concentrations with
their corresponding MIC values to assess if
the 200-Ìg disk could be used alone to accu-
rately detect both low- and high-level mupiro-
cin resistance. This would save time and re-
duce cost. The results are as shown in table 4.
With the 5-Ìg disk, growth to the edge of the
disk (zone size 6 mm) was obtained with
MICs greater than 32 mg/l, but this did not
distinguish between low- and high-level resis-
tance. On the other hand, growth of the organ-
ism to the edge of the 200-Ìg disk correspond-
ed with MIC 1512 mg/l, and different zone
sizes corresponded with different MIC val-
ues.
Transfer of Mupirocin Resistance
Genetic studies conducted earlier [24]
demonstrated that the S. haemolyticus isolate
CN216 carried five plasmids whose sizes were
approximately 40, 24, 3.5, 1.8 and 1.6 kb. In
experiments designed to study the genetic na-
ture of the mupirocin resistance determinant
of CN216, it was demonstrated that the high-
level mupirocin resistance was carried out on
a conjugative plasmid which was transferable
to clinical isolates of S. epidermidis, S. hae-
molyticus and S. saprophyticus.
Discussion
Plasmid-mediated resistance to high-level
mupirocin has been reported in S. aureus [17–
20] and CNS [18, 25] with resistance reported
after prolonged use of mupirocin in a few
institutions [6, 14]. The results presented here
have demonstrated that 94% of the staphylo-
cocci isolated in a burns unit were fully sus-
ceptible to mupirocin after 2 years of contin-
uous use of mupirocin for treatment of sta-
phylococcal infections and the eradication of
colonization. The low level of resistance to
mupirocin that was observed is in agreement
with those of other published reports [5, 6, 8].
However, it was in contrast to the reports of
Kauffman et al. [6] and Moy et al. [14], where
resistance to mupirocin developed after pro-
longed use. It is important to note that while
Kauffman et al. [6] and Moy et al. [14] used
mupirocin for more than 10 days at a time on
a patient which led to the development of
resistance, mupirocin is usually administered
for 5 days per patient in our unit. This prac-
tice, which is in accordance with the recom-
mendations of the manufacturer of mupirocin
[15], may have helped to keep the level of
resistance low. Our finding was reassuring be-
cause it indicated that mupirocin was still an
effective agent against MRSA isolated in the
burns unit.
Characteristically, the MRSA isolates were
more resistant to other antimicrobial agents
than the MSSA. Also, methicillin resistance
was high among the CNS but this was compa-
rable to the incidence of methicillin resistance
reported for CNS in another Kuwait hospital
[22]. Nevertheless, mupirocin was equally ef-
fective against MRSA, MSSA and the CNS
irrespective of their resistance to other agents.
This is consistent with the absence of cross-
resistance between mupirocin and other anti-
biotics [2, 15]. Although the patient from
whom the resistant CNS was isolated had
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been treated with mupirocin previously, it is
not clear whether the S. haemolyticus isolate
developed the resistance during therapy or
whether the patient acquired an already resis-
tant strain. No staphylococcal isolates from
the burns unit were tested for resistance to
mupirocin prior to mupirocin use. Neverthe-
less, high-level mupirocin resistance has been
reported in some staphylococci isolated prior
to the production and clinical use of mupiro-
cin [18, 25]. Notwithstanding the original
source of the mupirocin resistance determi-
nant in the S. haemolyticus, its detection was
timely because it helped to raise the aware-
ness of staff to the presence of a potential
problem. Since then, all the MRSA from the
unit are tested for resistance to mupirocin.
The finding that the high-level resistance to
mupirocin in the S. haemolyticus was carried
on a conjugative plasmid which was transfer-
able to other staphylococci is of concern be-
cause it implies that the mupirocin resistance
genes can be readily transferred to other sta-
phylococci in vivo.
The results comparing MIC values of mu-
pirocin to the zone sizes obtained by the 5-Ìg
and 200-Ìg disks suggested that the 5-Ìg disk,
used alone, would give exaggerated levels of
resistance. On the other hand, using the 200-
Ìg disk alone would miss low-level resistance.
However, since the clinical significance of
low-level resistance is presently not clear, it
would be better to use the 200 Ìg to detect
high-level resistance if one were to choose
between the two disks, since only the high-lev-
el resistance is clinically significant at this
stage [1, 2]. It appears that strains expressing
low-level mupirocin resistance can be eradi-
cated with mupirocin treatment [27]. In addi-
tion, low-level resistance can be detected with
the 200-Ìg disk if the zone sizes are carefully
measured (table 4).
In conclusion, the results of this study
which demonstrates that mupirocin was high-
ly effective against the majority of staphylo-
coccal isolates in the burns unit is reassuring.
However, it also drew attention to the real
threat of high-level mupirocin resistance de-
veloping factor. This can occur by strains
developing resistance during therapy or by
acquiring resistant genes from other resistant
staphylococci which might be introduced into
the unit [26]. There is a strong need for con-
stant vigilance through surveillance so as to
detect any of these events early. Early detec-
tion of resistance and the institution of infec-
tion control measures will prevent the estab-
lishment and spread of high-level mupirocin-
resistant strains in the unit. Finally, the results
also emphasize the need for judicial use of
mupirocin according to the recommendations
of the manufacturer if the development of
resistance during therapy is to be avoided.
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